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S244 Poster Session ISAA (Kobayashi et al, BJH, 2006). Previously, outcomes for alterna-
tive donor sources have been inferior secondary to higher rates of
graft rejection, GVHD and increased mortality (Bacigalupo et al,
Blood, 2000).
Objective:Given the poor outcome of medical therapy for SAA (Be-
kassy et al, PBC, 2005) and the improvements in HLAmatching and
outcomes of transplants from alternative donor sources (Maury et al,
Haematologica, 2007), we investigated a risk-adapted AlloSCT ap-
proach in 22 consecutive patients.
Methods: Patients with\10 transfusions received reduced toxicity
conditioning: Cy 60 mg/kg + Flu 180 mg/m2 + rATG 8 mg/kg
(n5 10) or Bu 16 mg/kg + Flu 180 mg/m2 + Alemtuzumab 54 mg/
m2 (n5 3). 9 patients received myeloablative conditioning: Cy
200 mg/m2 + Flu 180 mg/m2 + rATG 8 mg/kg (n5 8) or Bu
16 mg/kg +Mel 135 mg/m2 + rATG 8 mg/kg (n5 1).
Results:M/F: 14/8, median age: 9.5 years (3-18yrs), median fol-
low-up: 19 months (1-85mos). Stem cell source: Well-MSD BM
(9 6/6, 3 5/6); PB (CD34 Selected) MUD (1 10/10, 2 9/10);
UCB (4 5/6, 3 4/6). All patients received Tacrolimus and myco-
phenolate mofetil as AGVHD prophylaxis (Osunkwo/Cairo et al,
BBMT, 2004). Median time to neutrophil and platelet engraft-
ment was 14 days (8-32 days) and 32.5 days (11-66 days), respec-
tively. 21 patients engrafted (95% CI: 77.2-99.9); 1 patient had
primary graft failure (4.5%). Day +100 mean chimerism was
96.4%, and patients did not differ by intensity of conditioning.
Among the 7 patients (31.8%) who developed grade 2-4
GVHD, risk was not associated with conditioning regimen, do-
nor source or HLA match. One-year OS was 71.6% (standard
error 9.8%, 95% CI 50.7-92.6%) and an association was not de-
tectable in regards to donor source, HLA disparity or condition-
ing intensity. Six patients died (27.3%) (multiorgan failure: 3,
extensive GVHD: 1, fungal infection: 1, TMA: 1). 3 patients
had secondary graft failure (16.6%) and 2 patients required a sec-
ond transplant secondary to adenovirus and pure red blood cell
aplasia. Our data suggest that a risk-adapted approach to Al-
loSCT from related and alternative donor sources is a feasible
strategy for treatment of newly diagnosed pediatric patients
with SAA.231
25-HYDROXY VITAMIN D DEFICIENCY IN PEDIATRIC PATIENTS FOL-
LOWING HEMATOPOIETIC STEM CELL TRANSPLANT
Apfelbaum, E.1, Vrooman, L.M.1, Lehmann, L.E.1, Bechard, L.J.2,
Duncan, C.N.1 1Dana-Farber Cancer Institute, Boston, MA; 2Children’s
Hospital, Boston, MA
Pediatric patients following hematopoietic stem cell transplant
(HSCT) are at increased risk for vitamin D deficiency due to
lack of sun exposure and sunscreen use, some medications, and
dietary insufficiency. We investigated the incidence of 25-OH vi-
tamin D deficiency in pediatric patients following HSCT. The
study population included 90 patients (52 male, 38 female). 11
subjects had autologous HSCTs and 79 received allogeneic
HSCTs. The median time from transplant was 177 days (range
13-6873 days). 76% of subjects were Caucasian, 8% Hispanic,
7% Asian, 5% African American, and 4% mixed ethnicity. The
underlying diseases were ALL (27.8%), AML/MDS (20%), non-
malignant hematologic disorder (18.9%), solid tumor (12.3%),
immunodeficiency (7.8%), CML (4.4%), lymphoma (4.4%), and
other disorder (4.4%). 27.8% of patients received corticosteroids
and 51.1% took calcineurin inhibitors at the time of enrollment.
At enrollment, 5 patients received multivitamins and 4 patients
took vitamin D supplements. The incidence of 25-OH vitamin
D insufficiency, defined as a level less than 30 ng/mL, was
87%. 53% of patients were deficient with levels less than 20
ng/mL. The median 25-OH vitamin D level was 18 ng/mL
(mean 21.1 ng/mL). Patients with deficiency were prescribed
50,000 IU of ergocalciferol orally once weekly for 6 weeks. 47 pa-
tients received supplementation and post-supplementation values
were available for 40 patients. 5 patients died prior to repeat test-
ing and levels were missing for 2 patients. Repeat post-supple-
mentation testing revealed a median level of 30 ng/mL. 12.5%(n5 5) of those supplemented remained deficient 20 ng/mL and
47.5% (n5 19) remained insufficient. This study highlights the
need to monitor pediatric patients for vitamin D deficiency. A
better understanding of the risk factors and appropriate treatment
for vitamin D deficiency following HSCT is needed.232
BUSULFAN + FLUDARABINE, AN EFFECTIVE AND LOW TOXIC REGIMEN
IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT DISEASES
Flinsenberg, T.W.H.1, Bartelink, I.H.2, Ververs, T.F.T.T.2,
Bierings, M.1, Boelens, J.J.1 1UMCU, Utrecht, Netherlands; 2UMCU,
Utrecht, Netherlands
Background: Busulfan as myeloablative agent is used in condition-
ing prior to pediatricHSCT:mainly in combination with cyclophos-
phomide. We recently found a clear association between busulfan
exposure and outcomes (survival/event free survival). However, tox-
icity leading tomorbidity and associatedmortality remains a limiting
factor. Comparison studies in adults showed a favorable toxicity pro-
file for fludarabine + busulfan (FludBu) compared to the conven-
tional BuCy regimen. In paediatrics, limited data is available
regarding this regimen. FludBu was recently introduced to replace
the BuCy regimen in our center for myeloid malignancies and all
non-malignant indications. We compared the outcomes with our
BuCy historic controls.
Methods: Fludarabine was given in 1 hour prior to a 3 hour infusion
of once daily busulfan. The target area under the curve (AUC) for Bu
was. 74 mg*h/L (in total) in both groups. Busulfan dose targeting,
based on therapeutic drug monitoring was performed before the sec-
ond dose. Primary endpoints were event free survival (EFS) and sur-
vival. Secondary endpoints were acute graft-versus-host disease
(aGvHD), neutropenic period and the number of erythrocytes and
thrombocytes transfusions. A risk factor analysis was performed us-
ing univariable and multivariable COX regression.
Results: 13 patients were included in the FludBu group (median
follow up median 119 days; range 42-1593) and 44 in the BuCy
group (710 days; range 6-1686). The groups were comparable re-
garding donor source, age, gender, indication for SCT and match-
grade. EFS and Survival in FludBu and BuCy was 85% vs 71%
(NS) and 92% vs. 73% (NS), respectively. No difference in
aGvHD ($grade 2) was found between the 2 groups. The period
of neutropenia was median 12 in the FludBu group compared to
20.5 in the BuCy group (HR 0.38, p5 0.05, CI95% 0.20-0.75).
The median number of erythrocytes transfusion was 1 (range 1-
13) in the FludBu group and 5 (0-22) in the BuCy group
(p5 0.20) and thrombocyte infusions 5 (range 0-33) vs 10 (range
2-44)(p5 0,15).
Conclusions: Busulfan with a total target AUC of .74 mg*h/l in
combination fludarabine showed to be an effective and low toxic reg-
imen. Interesting is the significantly shorter neutropenic period and
lower number of transfusions (erythrocytes and thrombocytes)
needed in the FludBu group in comparison to BuCy. Although
a small series, FludBu showed promising results. Further follow up
and extension of the series is needed.233
PERI-TRANSPLANT INFECTIONS IN UNRELATED CORD BLOOD TRANS-
PLANTATION AND THEIR INFLUENCE ON OUTCOME
Alsultan, A., Giller, R.H., Gao, D., Bathurst, J., Hild, E.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and University of Colorado Denver, Aurora, CO
Infection in the peri-transplant period is a major cause of
morbidity and mortality post-transplant. The nature of peri-
transplant infections and their influence on outcome post unre-
lated cord blood transplant (UCBT) need to be further eluci-
dated.
Methods:We reviewed peri-transplant infections in 81 consecutive
UCBT. All culture-documented infections were reviewed starting 3
months pre-transplant through the first 100 days post-transplant.
Acute GVHD (aGVHD) II-IV, aGVHD III-IV, chronic GVHD
(cGVHD), and event free survival (EFS) were used as endpoints.
